Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE) - PubMed
5 hours ago
- #severe asthma
- #biologic therapy
- #clinical trial
- Depemokimab is an ultra-long-acting biologic with high interleukin-5 binding affinity, enabling twice-yearly dosing.
- The NIMBLE trial investigated switching severe asthma patients from mepolizumab/benralizumab to depemokimab.
- Primary endpoint: Annualized rate of clinically significant exacerbations over 52 weeks (non-inferiority margin: 1.28).
- Non-inferiority was not met (rate ratio: 1.16 [0.98 to 1.38]).
- Exacerbation rates were low in both groups, with symptom control and lung function maintained.
- Adverse events were comparable between depemokimab and active comparator groups.
- First randomized controlled switch trial suggests safe transition to twice-yearly depemokimab.